Posters

Comparison of nepafenac 0.3% with combined dexamethasone and bromafenac in prevention of intraocular inflammation after cataract surgery

Poster Details

First Author: I.Halkiadakis GREECE

Co Author(s): I. Markopoulos   A. Makris   A. Andreas   S. Skouriotis   V. Konstantinidou        

Abstract Details

Purpose:

To compare the efficacy of nepafenac 0.3% ophthalmic suspension with the combine treatment of dexamethasone and bromfenac in controlling macular swelling and other manifestations of inflammation after uneventful cataract surgery.

Setting:

Ophthalmiatrion Athinon Eye hospital

Methods:

Patients at low risk for postoperative inflammation were randomized to receive topical bromfenac 0.09% twice daily for 2 weeks and dexamethasone 0.1% 4 times daily with 1 drop less per day every following week or nepafenac 0.3% once a day for one month after cataract surgery. Postoperative swelling of the macula was assessed with ocular coherence tomography. Inflammation, corrected distance visual acuity, ocular discomfort, and visual complaints were also recorded. The patients were examined the next day, 1 week 4 weeks and 12 weeks after the operation.

Results:

One hundred sixty eyes were included in this prospective study. Three eyes (3.75%) in the nepafenac group and 1 eye (1.25%) in the combined treatment group showed relapse of intraocular inflammation in the 4th week visit. Two eyes in the nepavenac group (2.5%) and no eye in the combined treatment group developed macular edema in the 12 week visit. If we exclude the eyes which developed macular edema mean central macular thickness was 277 mm in the nepavenac group, and 281 mm in the combination treatment group 12 weeks after the operation. No difference was statistically significant.

Conclusions:

Topical nepafenac is an efficient anti-inflammatory regimen after cataract surgery.

Financial Disclosure:

None